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INTRODUCTION
Genetic factors may explain the differences in individual sensitivity
to the psychosis-inducing effects of cannabis.1,2 In view of the
converging data from candidate gene and genome-wide associa-
tion studies that the D2-AKT1 signaling pathway is relevant for the
pathophysiology and outcome of schizophrenia,3 and on the basis
of previous association between cannabis-related psychosis and
both DRD2 (rs1076560)1 and AKT1 (rs2494732),2 we hypothesized
that these polymorphisms interact in increasing the risk of
psychosis in cannabis users. We expected the genetic pathway
× cannabis use interaction model to better predict the individual’s
odds of psychotic disorder than the single candidate gene×
cannabis use interaction model.
MATERIALS AND METHODS
Participants were recruited as part of the Genetic and Psychosis
project (GAP),2 a case–control study, carried out at the Institute of
Psychiatry, London. All patients presenting to the Adult services
(18–65 years) of the South London and Maudsley Mental Health
NHS Foundation Trust, between December 2005 and October
2010, with their ﬁrst episode of psychosis, were recruited into the
study. Over the same time frame, from the area served by the
mental health units, we recruited a sample of control subjects,
aged 18–65 years, representing the local population in terms of
ethnicity and other main sociodemographics according to the
appropriate census data (www.statistics.gov.uk/census). Using the
same methodology as in ref. 2, only patients with a diagnosis of
nonorganic psychosis (International Classiﬁcation of Diseases, 10:
F20–F29 and F30–F33) were included, and control subjects were
excluded if they met criteria for a psychotic disorder or if they
reported a previous diagnosis of psychotic illness. For a more
detailed description of the GAP study methods, (see refs 1, 2).
The data presented here are based on the subset of the whole
GAP sample (450 participants (222 ﬁrst-episode psychosis patients
and 228 healthy individuals) with complete information on the
following: (i) sociodemographics (age, gender, and self-reported
ethnicity); (ii) lifetime use of cannabis, stimulants, tobacco, and
alcohol; and (iii) DRD2 rs1076560 and AKT1 rs2494732 genotypes.
To conﬁrm self-report of ethnicity, genetic ancestry was derived
using a panel of 57 ancestry-informative genetic markers, as
performed previously.2 These were genotyped using iPLEX
technology developed for the MassArray platform (Sequenom,
San Diego, CA, USA). Ancestry scores were derived using the
program Structure to implement a model-based (Markov Chain
Monte Carlo) clustering algorithm. Having determined the best
solution for K (the probable true number of underlying genetic
groups) in initial analyses, individuals who scored between 96 and
100% for genetic cluster membership were used to create a three-
way ancestral axis on the basis of Black African (N= 81), European
Caucasian (N= 118), and Asian (N= 16) ancestry. These reference
groups were used to index genetic ancestry for the remaining
sample. Further information on the makeup of the marker panel as
well as a ﬁgure reporting plots of three-way ancestral axis on the
basis of Black African, European Caucasian, and Other are available
on request. Ninety percent (N= 407) of participants had informa-
tion on both self-reported ethnicity and ancestry markers. The
level of overall agreement between self-reported and genetic
ethnicities (96%) was reassuringly high.
Multivariable logistic regressions were used to evaluate the
main and interaction effects between two measures of cannabis
exposure (lifetime use and frequency of use) and DRD2 rs1076560/
AKT1 rs2494732 (individuals carrying one or more of each of the
two ‘risk’ alleles (DRD2 T and AKT1 C); individuals carrying one or
more ‘risk’ alleles of only one of the genes (DRD2 T or AKT1 C);
individuals carrying no ‘risk’ alleles) on presence of a psychotic
disorder, after adjusting for potential confounders (sociodemo-
graphics and other drug use). The interaction model examined the
probability of having a psychotic disorder among cannabis users
carrying ‘risk’ allele(s) from both (DRD2 T carriers/AKT1 C carriers)
or only one of the genes (DRD2 T carriers/AKT1 TT and DRD2 GG/
AKT1 C carriers) compared with DRD2 GG/AKT1 TT subjects. Odds
ratio (OR) of psychosis among cannabis-naive subjects carrying
‘risk’ allele(s) from both or only one of the genes were also
calculated from the estimates provided by the model.
The study was granted ethical approval by the South London
and Maudsley and Institute of Psychiatry Local Research Ethics
Committee. All cases and control subjects who were included
gave informed written consent, signing the consent document, to
the publication of data originating from the study.
RESULTS
First-episode psychosis and control subjects differed signiﬁcantly
for some demographic characteristics and in their patterns of
drug use. However, the DRD2/AKT1 genotype was not associated
with any sociodemographic variable or cannabis use (all P40.1;
Table 1). A multivariable logistic regression adjusting for the
modeled potential confounders showed a signiﬁcant interaction
between DRD2 rs1076560/AKT1 rs2494732 genotypes and lifetime
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Table 1. Demographic measures and patterns of drug use in FEP patients and control subjects
FEP patients, n= 222 Control subjects, n=228 Statistical comparisons
M± s.d. M± s.d.
Age of psychosis onset 26.07± 6.19
Age at assessment 26.96± 6.46 28.17± 7.12 F= 3.54, P= 0.06 (ANOVA)
Range 18–44 18–44
Distribution χ2 = 5.23; P= 0.07
18–29 151 (68.0) 145 (63.6)
30–39 59 (26.6) 57 (25)
40–49 12 (5.4) 26 (11.4)
Gender χ2, P40.1
Male 149 (67.1) 141 (61.8)
Female 73 (32.9) 87 (38.2)
Self-reported ethnicity χ2 = 35.44, Po0.001
White Caucasian 72 (32.4) 134 (58.8)
Black Caribbean 68 (30.6) 37 (16.2)
Black African 57 (25.7) 31 (13.6)
Asian/other 25 (11.3) 26 (11.4)
DRD2 rs1076560/AKT1 rs2494732 P40.1
No ‘risk’ alleles 54 (24.3) 57 (25)
One ‘risk’ allele 124 (55.9) 133 (58.3)
Two ‘risk’ alleles 44 (19.8) 38 (16.7)
Tobacco use χ2 = 27.19, Po0.001
Nicotine dependence 157 (70.7) 106 (46.5)
Not nicotine dependence 65 (29.3) 122 (53.5)
Stimulant use P40.1
Yes 93 (41.9) 81 (35.5)
Never 129 (58.1) 147 (64.5)
Alcohol use χ2 = 23.58, Po0.001
Harmful drinking behavior 157 (70.7) 203 (89)
Not harmful drinking behavior 65 (29.3) 25 (11)
Cannabis use χ2 = 4.00, P= 0.05
Yes 158 (71.2) 142 (62.3)
No ‘risk’ alleles 40 (25.3) 36 (25.4)
One ‘risk’ allele 89 (56.3) 82 (57.7)
Two ‘risk’ alleles 29 (18.3) 24 (23.2)
Never 64 (28.8) 86 (37.7)
No ‘risk’ alleles 14 (21.9) 21 (24.4)
One ‘risk’ allele 35 (54.7) 51 (59.3)
Two ‘risk’ alleles 15 (23.4) 14 (16.3)
Frequency of use χ2 = 14.38, Po0.001
Dailya 92 (61.1) 43 (39.8)
No ‘risk’ alleles 24 (26.1) 11 (25.6)
One ‘risk’ allele 51 (55.4) 22 (51.2)
Two ‘risk’ alleles 17 (18.5) 10 (23.2)
Weekly or lessa 52 (38.9) 65 (60.2)
No ‘risk’ alleles 12 (23.1) 18 (27.7)
One ‘risk’ allele 29 (55.7) 37 (56.9)
Two ‘risk’ alleles 11 (21.2) 10 (15.4)
No detailsa 14 34
Age of ﬁrst usea 16.51 ± 4.99 16.51 ± 5.81 P40.1 (ANOVA)
No ‘risk’ alleles 16.35± 4.63 16.20± 7.46
One ‘risk’ allele 16.51± 5.03 16.64± 5.10
Two ‘risk’ alleles 16.66± 5.35 16.6± 4.83
Age of onset minus age of ﬁrst useb 9.56± 7.00
Abbreviations: ANOVA, analysis of variance; FEP, ﬁrst-episode psychosis; no ‘risk’ alleles, DRD2 GG/AKT1 TT; one ‘risk’ allele, DRD2 T carriers/AKT1 TT+DRD2 GG/
AKT1 C carriers; two ‘risk’ alleles, DRD2 T carriers/AKT1 C carriers.
aIn those who had ever used cannabis.
bNo patient started to use cannabis for the ﬁrst time after the psychosis onset.
Data are presented as M± s.d. or n (%).
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cannabis use on probability of suffering from a psychotic disorder.
The analysis showed an increasing probability of suffering from a
psychotic disorder in cannabis users depending on DRD2/AKT1
(N= 450, likelihood ratio test = 7.66; P= 0.022). When compared
with the no ‘risk’ allele group, cannabis users carrying ‘risk’ allele(s)
from only one (OR = 3.50; 95% conﬁdence interval: 1.14, 10.77) or
both the genes (OR = 7.30; 95% conﬁdence interval: 1.58, 33.64)
showed increased odds of having psychotic disorder. On the
contrary, among those who had never used cannabis, carrying
‘risk’ allele(s) from only one (OR = 0.29; 95% conﬁdence interval:
0.09, 0.88) or both the genes (OR= 0.14; 95% conﬁdence interval:
0.03, 0.63) was associated with lower odds of suffering a psychotic
disorder compared with the DRD2 GG/AKT1 TT genotype
(Figure 1a). A second multivariable logistic regression adjusting
for the potential confounders showed a signiﬁcant interaction
between DRD2/AKT1 and lifetime frequency of cannabis use on
risk of psychosis (N= 402, likelihood ratio test = 11.91; P= 0.042).
Among both occasional and daily cannabis users, subjects carrying
‘risk’ allele(s) from one or both genes showed increased odds of
having psychotic disorder when compared with the no ‘risk’ allele
group; however, only among daily cannabis users did the
increased odds of psychosis reach signiﬁcance. In particular, there
was a weak association between daily use and psychosis risk in
subjects carrying ‘risk’ allele(s) from only one gene (OR= 3.47; 95%
conﬁdence interval: 0.99, 12.13) but a strong association between
daily use and psychosis risk in subjects carrying ‘risk’ allele(s) from
both the genes (OR = 10.06; 95% conﬁdence interval: 1.83, 55.17).
On the contrary, among those who had never used cannabis,
carrying ‘risk’ allele(s) from only one (OR= 0.29; 95% conﬁdence
interval: 0.08, 1.01) or both the genes (OR= 0.10; 95% conﬁdence
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Figure 1. (a) Interaction between DRD2 rs1076560/AKT1 rs2494732 and lifetime cannabis use on psychosis risk. (b) Interaction between DRD2
rs1076560/AKT1 rs2494732 and lifetime frequency of cannabis use on psychosis risk. *Adjusted for gender, age, ethnicity, nicotine
dependence, stimulants use, and harmful drinking behavior.
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interval: 0.02, 0.55) was associated with lower odds of suffering a
psychotic disorder compared with the DRD2 GG/AKT1 TT genotype
(Figure 1b).
DISCUSSION
The present results suggest an interaction between DRD2 rs1076560
and AKT1 rs2494732 genotypes on psychosis risk among cannabis
users. Individuals carrying the DRD2 T allele or the AKT1 C allele have
an increased psychosis risk in the context of cannabis use; however,
the risk is especially increased in subjects who carry ‘risk’ alleles from
both genes. In line with previous ﬁndings,1,2 the psychosis risk in
cannabis users depends on the frequency of use, with the highest
probability of psychotic disorder among daily users carrying both the
risk variants. Our results indicate a model of interaction known as
‘qualitative G×E interaction’ with a crossover pattern: carriers of risk
allele(s) for one of the two genes (DRD2 rs1076560 T or AKT1
rs2494732 C allele), compared with individuals carrying no ‘risk’
alleles (DRD2 rs1076560 GG/AKT1 rs2494732 TT), have a lower
probability of psychotic disorder if they never used cannabis but a
higher probability if they have a history of cannabis use, especially of
daily use. Similarly, carriers of both the ‘risk’ alleles (DRD2 rs1076560 T
allele and AKT1 rs2494732 C allele), compared with the other groups,
have the lowest probability of psychotic disorder if they never used
cannabis but the highest probability if they have a history of
cannabis use, especially of daily use. Our ﬁndings are in line with
previous results in the ﬁeld1,2,4,5 and indicate that speciﬁc minor
alleles may prevent or promote the risk for psychosis depending on
the presence and degree of cannabis use. Such ﬁndings require
validation in experimental designs and animal studies where both
changes in the exposure and in the genotype can be modeled.
Striatal dopamine is altered in both schizophrenia patients and
cannabis users,6 and cannabis-induced psychosis is related to the
effects of cannabis on the striatum.7 The DRD2 T allele has been
associated with both greater levels of striatal dopamine8 and
cannabis-related psychosis,2 and is linked with AKT1 expression
and psychosis-related endophenotypes by interaction with AKT1
rs1130233.3 Rs1130233 is in high linkage disequilibrium with
rs2494732 (r2 = 0.45, D′=0.94) and both single-nucleotide poly-
morphisms have been implicated in cannabis-related psychosis,1,7
likely altering striatal function.7 Cannabinoids activate AKT1 signal-
ing downstream of D2,1,7 and schizophrenia patients with comorbid
substance dependence have been reported to have abnormal post-
synaptic D2 function.9 Consistent with this, our results suggest
vulnerability to the psychotogenic effects of cannabis use involving
genes that control dopamine signaling, particularly postsynaptically.
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